Research programme: VAP-1 inhibitors - Mallinckrodt

Alternative Names:
RTU-009

Latest Information Update: 21 Feb 2018

Price :
*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator
R-Tech Ueno

Developer
Mallinckrodt plc

Class
Small molecules

Mechanism of Action
AOC3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

New Molecular Entity
Yes

Highest Development Phases

Preclinical
Cerebral infarction; Graft-versus-host disease

Most Recent Events

13 Feb 2018
Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc

07 Dec 2015
R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals